Adjuvant Therapy for Node-Negative Breast Cancer

K. C. Lee, Clyde B. Schechter, Melody A. Cobleigh, Stuart M. Lichtman, Daniel R. Budman, John H. Donohue, David M. Nagorney, Clive S. Grant, Jon A. Vanheerden, Michael G. Sarr, Sylvester Sterioff, Michael B. Farnell, Donald C. Mcilrath, John H. Pemberton, Peter Mucha, Robert A. Buckman, Kathleen I. Pritchard, Donald J. Sutherland, Robert G. Mackenzie, Ida AckermanMary A. Doherty, Pamela A. Catton, Ian F. Tannock, Bernard Fisher, Carol Redmond, Vincent T. Devita, Aron Goldhirsch, Richard D. Gelber, Monica Castiglione

Research output: Contribution to journalLetterpeer-review

11 Scopus citations


To the Editor: The articles on node-negative breast cancer (Feb. 23 issue)1 2 3 4 are very important. They provide further support for treating patients with this disease. However, I am troubled by some of their conclusions. Fisher et al.1,2 feel that all patients with node-negative cancer except those with tumors too small for estrogen-receptor analysis should be treated. This is not warranted by the data presented. First, the follow-up was only four years. Second, the benefit of treatment was seen only in disease-free survival and not in overall survival. This could mean that treatment only delays failure. Third, the treatment was not…

Original languageEnglish (US)
Pages (from-to)469-473
Number of pages5
JournalNew England Journal of Medicine
Issue number7
StatePublished - Aug 17 1989

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Adjuvant Therapy for Node-Negative Breast Cancer'. Together they form a unique fingerprint.

Cite this